Odevixibat
Composition
This formulation contain Odevixibat as active pharmaceutical ingrediant.
Indications
Odevixibat is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients who have not responded adequately to other treatments, and for the treatment of pruritus in patients with Alagille syndrome.
Side effects
Common side effects include diarrhea, abdominal pain, vomiting, and headache.
Precautions
Use caution in patients with a history of liver or gallbladder disease.
Contraindications
Odevixibat is contraindicated in patients with known hypersensitivity to the drug.
Dosage and administration
Once in a day, as directed by healthcare provider.
Countries
US, Europe
Available Forms
Tablets, Suspension
Manufacturing Services
Third Party Manufacturing Company WHO, GMP, EUGMP, USFDA, In India | Contract Manufacturing Organization (CMO) WHO, GMP, EUGMP, USFDA Services in India, Mumbai, Navi Mumbai| Contract Development and Manufacturing Organization (CDMO) WHO, GMP, EUGMP, USFDA - Services in India | Pharmaceutical Contract Manufacturing Company WHO, GMP, EUGMP, USFDA in Navi Mumbai, India | Top Pharmaceutical Product Exporters, Suppliers, Distributer WHO, GMP, EUGMP, USFDA in Mumbai